Free Trial

NLS Pharmaceutics (NLSP) Competitors

NLS Pharmaceutics logo
$2.29 +0.03 (+1.33%)
Closing price 02/18/2025 04:00 PM Eastern
Extended Trading
$2.27 -0.02 (-0.83%)
As of 02/18/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NLSP vs. ELEV, DTIL, IRD, VYNE, GRCE, ATNM, PASG, CLDI, OCX, and UBX

Should you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Elevation Oncology (ELEV), Precision BioSciences (DTIL), Opus Genetics (IRD), VYNE Therapeutics (VYNE), Grace Therapeutics (GRCE), Actinium Pharmaceuticals (ATNM), Passage Bio (PASG), Calidi Biotherapeutics (CLDI), OncoCyte (OCX), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry.

NLS Pharmaceutics vs.

Elevation Oncology (NASDAQ:ELEV) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elevation OncologyN/AN/A-$45.70M-$0.82-0.83
NLS PharmaceuticsN/AN/A-$12.17MN/AN/A

NLS Pharmaceutics' return on equity of 0.00% beat Elevation Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Elevation OncologyN/A -59.73% -40.05%
NLS Pharmaceutics N/A N/A N/A

Elevation Oncology has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500.

Elevation Oncology presently has a consensus target price of $7.20, suggesting a potential upside of 963.20%. Given Elevation Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Elevation Oncology is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elevation Oncology
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
NLS Pharmaceutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

83.7% of Elevation Oncology shares are owned by institutional investors. 8.1% of Elevation Oncology shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, NLS Pharmaceutics had 1 more articles in the media than Elevation Oncology. MarketBeat recorded 1 mentions for NLS Pharmaceutics and 0 mentions for Elevation Oncology. Elevation Oncology's average media sentiment score of 0.99 beat NLS Pharmaceutics' score of -0.20 indicating that Elevation Oncology is being referred to more favorably in the media.

Company Overall Sentiment
Elevation Oncology Positive
NLS Pharmaceutics Neutral

Elevation Oncology received 27 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 76.09% of users gave Elevation Oncology an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote.

CompanyUnderperformOutperform
Elevation OncologyOutperform Votes
35
76.09%
Underperform Votes
11
23.91%
NLS PharmaceuticsOutperform Votes
8
57.14%
Underperform Votes
6
42.86%

Summary

Elevation Oncology beats NLS Pharmaceutics on 8 of the 13 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NLSP vs. The Competition

MetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.24M$6.87B$5.77B$9.20B
Dividend YieldN/A2.90%5.29%3.98%
P/E RatioN/A9.4226.4419.51
Price / SalesN/A260.31449.4569.98
Price / CashN/A75.4646.0638.90
Price / BookN/A5.477.255.07
Net Income-$12.17M$123.25M$3.19B$222.54M
7 Day Performance-2.14%1.73%1.41%2.13%
1 Month Performance19.90%1.38%3.50%1.63%
1 Year Performance397.83%-0.12%20.82%16.41%

NLS Pharmaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NLSP
NLS Pharmaceutics
N/A$2.29
+1.3%
N/A+397.8%$8.24MN/A0.006Gap Up
ELEV
Elevation Oncology
2.6537 of 5 stars
$0.62
-1.3%
$7.20
+1,055.9%
-77.0%$36.83MN/A-0.7640Gap Up
DTIL
Precision BioSciences
4.5454 of 5 stars
$4.79
+1.9%
$37.67
+686.4%
-56.5%$36.74M$48.73M79.85200Positive News
Gap Up
IRD
Opus Genetics
2.0986 of 5 stars
$1.14
-0.9%
$8.00
+601.8%
N/A$35.99M$8.38M-1.0514News Coverage
VYNE
VYNE Therapeutics
2.6366 of 5 stars
$2.43
+0.8%
$6.88
+182.9%
+10.1%$35.84M$420,000.00-2.8330Gap Down
GRCE
Grace Therapeutics
2.6699 of 5 stars
$3.51
+8.3%
N/AN/A$35.59MN/A-3.48N/AEarnings Report
Analyst Forecast
High Trading Volume
ATNM
Actinium Pharmaceuticals
1.7201 of 5 stars
$1.13
+0.9%
$7.40
+554.9%
N/A$35.26M$80,000.00-0.8130Gap Up
PASG
Passage Bio
3.1847 of 5 stars
$0.57
-3.6%
$7.75
+1,259.4%
-57.7%$35.22MN/A-0.49130Gap Up
CLDI
Calidi Biotherapeutics
2.1424 of 5 stars
$1.32
+1.5%
$16.67
+1,162.6%
N/A$34.93M$50,000.000.0038Gap Up
OCX
OncoCyte
3.3273 of 5 stars
$2.07
+3.0%
$4.42
+113.4%
-10.0%$34.84M$1.50M0.00120
UBX
Unity Biotechnology
4.0574 of 5 stars
$2.04
-4.7%
$7.33
+259.5%
+3.6%$34.37M$240,000.00-1.5660Negative News
Gap Up

Related Companies and Tools


This page (NASDAQ:NLSP) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners